MD
AP-HM, AMU
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
As a an internal medicine physician, I am often faced with patients who have conditions that result from immune system dysfunctions. These inflammatory or autoimmune diseases are often rare diseases whose causes and symptoms are misunderstood: lupus, myositis autoimmune diseases, immune deficiencies in adults, systemic fibrosis, etc.
Like Marseille Immunopole, our discipline is positioned at the interface of different medical specialties, but also of fundamental and translational research. For many years our service at the Timone Hospital has collaborated with researchers including the ” Natural Killer Cells and Innate Immunity” team of Eric VIVIER at CIML. Together, we have developed a laboratory at the Conception Hospital specializing in the functional exploration of these lymphocytes and rare lymphocyte populations. We are conducting studies to better understand their involvement in diseases such as Systemic Lupus Erythematosus, Immune Thrombocytopenia Purpura (ITP) or IgG4-related diseases. The laboratory has also developed a routine battery of tests to quantify and qualify the activity of NK cells, T helper cells (Th) and Innate Lymphoid Cells (ILCs), particularly in clinical trials.
#clinique #rechercheThe Pioneer Project is unique as a strong public/private partnership between academia, a medical cancer center, 3 biotechs and a major pharma
Bernard A. FOX
Providence Cancer Institute, Portland, Oregon | UbiVac
Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.
Marcel BLOT-CHABAUD
VRCM
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
Norbert VEY
AMU, IPC
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Delphine BADINAND
APHM